Literature DB >> 3178466

Femoropopliteal reconstruction for claudication. The risk to life and limb.

K C Kent1, M C Donaldson, C E Attinger, N P Couch, J A Mannick, A D Whittemore.   

Abstract

The current study was undertaken to examine the results of femoropopliteal bypass grafting with intermittent claudication as the indication. Of 1173 infrainguinal reconstructions carried out on our service during the past decade, 249 (21%) consecutive femoropopliteal grafts were performed for disabling claudication in 191 patients. The primary five-year cumulative patency rates were 78% for autogenous vein and 52% for polytetrafluoroethylene grafts. There were two (0.8%) 30-day operative deaths and a subsequent five-year amputation rate of 2.4% for both groups. Femoropopliteal reconstruction for claudication may therefore be carried out with acceptably low operative mortality and a subsequent amputation rate comparable with that anticipated from the natural history of the disease. While the five-year patency rate is significantly higher utilizing autogenous vein grafts, symptomatic relief may be expected with prosthetic grafts in approximately half the patients without incurring a higher risk of limb loss.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3178466     DOI: 10.1001/archsurg.1988.01400340022003

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

Review 1.  Current techniques for infrainguinal arterial reconstruction.

Authors:  A Whittemore
Journal:  Jpn J Surg       Date:  1990-11

2.  Cuffed anastomosis for above-knee femoropopliteal bypass with a stretch expanded polytetrafluoroethylene graft.

Authors:  Yoshinori Inoue; Norihide Sugano; Masatoshi Jibiki; Siro Kitamura; Takehisa Iwai
Journal:  Surg Today       Date:  2008-07-31       Impact factor: 2.549

3.  Benefits of arterial reconstruction in claudication.

Authors:  T Ohta; R Kato; I Sugimoto; K Hida; J Hachiya; E Mihara; T Hasegawa; Y Imamura; H Ishibashi; M Hosaka
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.